Page 180 - ESHRE2019

References
De Wert GM, Dondorp WJ, Knoppers BM. Preconception care and genetic risk: ethical issues. J Community Genet 2012;3:221–8.
Pascale C, Kumar N, Yarnall S, Lee K, Chen SH. Understanding the patient experience: comparing carriers and non‐carriers as identified by an expanded carrier panel. Fertil Steril 2016;105(2 Suppl):e33.
Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CHG, Forzano F, et al. Responsible implementation of expanded carrier screening. Eur J Hum Gen Open 2016;24:e1–12.
Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, et al. Expanded carrier screening in reproductive medicine—points to consider. A joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal‐Fetal Medicine. Obstet Gynecol 2015;125:653–62.
McIntyre MD. The potential for products liability actions when artificial insemination by an anonymous donor produces children with genetic defects. Dick L Rev 1993;98:519.
21
References
Lindheim SR, Jaeger AS. Expanded preconception carrier screening in clinical practice: cutting the Gordian knot. Fertil Steril 2015;104:281–2.
Musci TJ, Moyer K. Prenatal carrier testing for fragile X: counseling issues and challenges. Obstet Gyn Clin N Am 2010;37:61–70.
22
178
174